A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes Following Acute Myocardial Infarction

A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes Following Acute Myocardial Infarction

Background: Oral factor XIa (FXIa) inhibitors may modulate coagulation to prevent thromboembolic events without significantly increasing bleeding. We explored the pharmacodynamics, safety, and efficacy of the oral FXIa inhibitor asundexian for secondary prevention after acute myocardial infarction (...

Teljes leírás

Elmentve itt :
Bibliográfiai részletek
Szerzők: Rao Sunil V.
Kirsch Bodo
Bhatt Deepak L.
Budaj Andrzej
Merkely Béla Péter
Kollaborációs szervezet: PACIFIC AMI Investigators
Falukozi József
Ruzsa Zoltán
Tomcsányi János
Csanádi Zoltán
Herczeg Béla
Kőszegi Zsolt
Vorobcsuk András
Kiss Róbert
Baranyai Csaba
Dezsi Csaba
Lupkovics Géza
et al
Dokumentumtípus: Cikk
Megjelent: 2022
Sorozat:CIRCULATION 146 No. 16
Tárgyszavak:
Klinikai orvostan
doi:10.1161/CIRCULATIONAHA.122.061612

mtmt:33073422
Online Access:http://publicatio.bibl.u-szeged.hu/25941
Leíró adatok
Tartalmi kivonat:Background: Oral factor XIa (FXIa) inhibitors may modulate coagulation to prevent thromboembolic events without significantly increasing bleeding. We explored the pharmacodynamics, safety, and efficacy of the oral FXIa inhibitor asundexian for secondary prevention after acute myocardial infarction (MI).
Terjedelem/Fizikai jellemzők:1196-1206
ISSN:0009-7322

Hasonló tételek